What is MGUS?
MGUS stands for monoclonal gammopathy of undetermined significance. It is a condition in which a small group of identical (clonal) plasma cells in the bone marrow makes an abnormal antibody protein, called a monoclonal protein or M-protein (also known as a paraprotein).
Plasma cells normally make many different antibodies to fight infection. In MGUS, one clone of plasma cells makes large amounts of a single antibody. This shows up as a sharp spike on a blood test called protein electrophoresis.
MGUS is not cancer and usually causes no symptoms. It is very common: about 3 in 100 people over 50 have it, and most never know.
It is usually found by chance during blood tests done for other reasons, such as checking kidney function, anaemia, nerve problems or a high protein level in the blood.
The importance of MGUS is that it carries a small risk of turning into a more serious condition. These include multiple myeloma, AL amyloidosis, Waldenstrom macroglobulinaemia and some lymphomas. The risk is about 1% per year.
Almost all cases of multiple myeloma are preceded by MGUS (Landgren et al., 2009). For this reason, people with MGUS are offered regular blood test monitoring.
1. Key facts at a glance
| Feature | Details |
|---|---|
| What it is | A small plasma cell clone making a monoclonal protein |
| Is it cancer? | No; it is a precursor condition |
| How common | About 3% of people over 50 and about 5% over 70 |
| Who is affected | More common in men, older people and Black people |
| Symptoms | Usually none |
| Risk of progression | About 1% per year overall |
| Treatment | Not needed; regular monitoring instead |
| Life expectancy | Normal or near normal for most people |
2. Types of MGUS
There are three main types, depending on which part of the antibody is made in excess. Each type tends to progress to different diseases.
| Type | What is found | What it may progress to |
|---|---|---|
| Non-IgM MGUS (IgG, IgA) | IgG or IgA M-protein; most common type, about 80% | Multiple myeloma, AL amyloidosis |
| IgM MGUS | IgM M-protein; about 15% | Waldenstrom macroglobulinaemia, lymphoma, AL amyloidosis |
| Light-chain MGUS | Only excess free light chains, no whole antibody | Light-chain myeloma, AL amyloidosis |
How MGUS is defined
The International Myeloma Working Group defines non-IgM MGUS as all of the following (Rajkumar et al., 2014):
- M-protein below 30 g/L in the blood
- Clonal plasma cells below 10% of the bone marrow, if a marrow test is done
- No damage to organs caused by the plasma cells, such as high calcium, kidney damage, anaemia or bone lesions (known as “CRAB” features)
- No AL amyloidosis or other related disease
If the M-protein is 30 g/L or more, or plasma cells reach 10% or more, without organ damage, the condition is called smouldering myeloma. That condition carries a higher risk of progression.
How MGUS differs from related conditions
| Condition | M-protein | Bone marrow plasma cells | Organ damage | Treatment |
|---|---|---|---|---|
| MGUS | Below 30 g/L | Below 10% | None | Monitoring only |
| Smouldering myeloma | 30 g/L or more | 10-59% | None | Monitoring; treatment for some high-risk cases |
| Multiple myeloma | Usually present | 10% or more | Yes (high calcium, kidney damage, anaemia, bone lesions) or other myeloma-defining features | Active treatment |
| AL amyloidosis | Often small | Often below 10% | Yes, from amyloid deposits | Active treatment |
The main difference between MGUS and myeloma is therefore not only the amount of protein, but whether the clone is causing harm to the body.
3. Causes and risk factors
The cause of MGUS is not fully understood. It probably results from a combination of ageing of the immune system, genetic factors and long-term immune stimulation.
| Risk factor | Notes |
|---|---|
| Age | The strongest factor; prevalence rises steadily after 50 |
| Sex | Slightly more common in men |
| Ethnicity | About twice as common in Black people as in white people |
| Family history | Close relatives of people with MGUS or myeloma have a higher risk |
| Obesity | Linked with a modestly higher risk |
| Some exposures | Pesticides and certain chemicals have been linked in studies |
| Chronic inflammation or autoimmune disease | Associated in some studies |
In a large study of people in Minnesota, MGUS was found in 3.2% of people aged 50 or over and 5.3% of those aged 70 or over (Kyle et al., 2006).
4. How does it look
MGUS has no visible signs on the body. People with it look and feel well, and it cannot be detected by examination.
It “looks” like something only on laboratory tests:
| Test | What is seen |
|---|---|
| Serum protein electrophoresis | A narrow, sharp band or spike (the “M-spike”) in the gamma or beta region, instead of the normal broad hump |
| Immunofixation | Identifies the type of M-protein, for example IgG kappa or IgA lambda |
| Serum free light chains | May show an abnormal kappa-to-lambda ratio |
| Full blood count, calcium, kidney tests | Normal in MGUS; abnormal results suggest another condition |
| Bone marrow (if done) | A small proportion of clonal plasma cells, under 10% |
When MGUS is not “undetermined”
Sometimes the M-protein itself causes harm even though the clone is small. Doctors then use more specific names:
| Condition | Meaning |
|---|---|
| MGRS (monoclonal gammopathy of renal significance) | The protein damages the kidneys (Leung et al., 2019) |
| MGCS (monoclonal gammopathy of clinical significance) | The protein damages other organs, such as the nerves or skin (Fermand et al., 2018) |
| IgM-related neuropathy | The IgM protein attacks nerves, causing numbness and unsteadiness |
These conditions often need treatment aimed at the clone, even though they are not cancers.
5. Symptoms
By definition, MGUS itself does not cause symptoms. People with MGUS are usually completely well.
Some people with MGUS have a slightly higher risk of:
- Bone thinning (osteoporosis) and fractures
- Infections
- Blood clots in the veins
- Peripheral neuropathy (numbness or tingling in the feet), especially with IgM MGUS
Warning signs of progression
New symptoms may mean MGUS has progressed or that a related condition has developed. Tell your doctor promptly about:
| Symptom | Possible meaning |
|---|---|
| New bone pain, especially in the back or ribs | Myeloma |
| Increasing tiredness, paleness or breathlessness | Anaemia from myeloma or Waldenstrom |
| Frequent or severe infections | Weakened immune system |
| Excessive thirst, confusion or constipation | High calcium |
| Foamy urine or swollen legs | Kidney damage or AL amyloidosis |
| Numbness or tingling in the hands or feet | Neuropathy or amyloidosis |
| Swollen lymph glands, night sweats, weight loss | Lymphoma or Waldenstrom |
| Nosebleeds, blurred vision, headaches | Thick blood (hyperviscosity) in IgM disease |
| Easy bruising around the eyes, large tongue | AL amyloidosis |
6. Diagnosis
MGUS is diagnosed when an M-protein is found and other conditions have been ruled out. Doctors usually do the following:
| Test | Purpose |
|---|---|
| Serum protein electrophoresis and immunofixation | Measure and type the M-protein |
| Serum free light chain assay | Measure kappa and lambda light chains and their ratio |
| Full blood count | Check for anaemia |
| Calcium and kidney function | Check for organ damage |
| Urine tests | Look for protein or light chains in the urine |
| Bone marrow biopsy | Not needed for everyone; done if risk is higher or results are unclear |
| Imaging | Low-dose whole-body CT, MRI or PET-CT if there is any concern about bone disease or higher-risk MGUS |
| NT-proBNP and urine albumin | Screen for amyloidosis when the light chain is abnormal |
For low-risk MGUS with normal blood tests, a bone marrow test and imaging are usually not needed.
7. Risk of progression
Large long-term studies from the Mayo Clinic found that MGUS progresses at about 1% per year, and the risk never disappears, even after decades (Kyle et al., 2002; Kyle et al., 2018).
Mayo Clinic risk model
Doctors use three simple risk factors (Rajkumar et al., 2005):
- M-protein of 15 g/L or more
- Non-IgG type (IgA or IgM)
- Abnormal free light chain ratio
| Number of risk factors | Risk group | Risk of progression at 20 years |
|---|---|---|
| 0 | Low risk | About 5% |
| 1 | Low-intermediate | About 21% |
| 2 | High-intermediate | About 37% |
| 3 | High risk | About 58% |
These figures do not take into account that many older people die of unrelated causes first. The real chance of developing myeloma or a related disease in a person’s lifetime is therefore lower.
About half of people with MGUS are in the low-risk group.
8. Management and follow-up
MGUS does not need treatment. Studies have not shown that treating MGUS prevents progression, and treatment would carry side effects.
Instead, people are monitored with regular blood tests so that progression can be picked up early.
| Risk group | Typical monitoring |
|---|---|
| Low risk | Repeat tests after 6 months; if stable, every 2-3 years or only if symptoms develop |
| Intermediate or high risk | Repeat tests after 6 months, then every year for life |
| IgM MGUS | Yearly tests, including a check for swollen glands and an enlarged spleen |
| Light-chain MGUS | Yearly free light chain and kidney checks |
Looking after your general health
- Bone health: ask about a bone density scan, vitamin D and calcium, and treatment if you have osteoporosis
- Vaccinations: keep up to date with flu, pneumococcal, COVID-19 and other recommended vaccines
- Infections: seek prompt treatment for infections
- Blood clots: be aware of signs of a clot, such as a painful swollen leg
- Medicines: tell your doctors you have MGUS before having contrast dye or certain drugs that could affect the kidneys
Should people be screened?
Routine screening of healthy people for MGUS is not recommended. Large studies are investigating whether screening could help catch myeloma earlier.
9. Outlook (prognosis)
For most people the outlook is excellent. MGUS usually remains stable for many years, and most people with it never develop myeloma or a related disease.
People with MGUS have slightly shorter survival on average than the general population in long-term studies. This is partly due to progression and partly due to associated conditions such as infections and fractures (Kyle et al., 2018).
If progression happens, regular monitoring means it is usually caught before serious complications develop. Modern treatments for myeloma and related conditions are much more effective than they were in the past.
10. Living with MGUS
Learning that you have an abnormal blood protein can cause worry, particularly when the word “myeloma” is mentioned. It helps to remember that MGUS is common, is not cancer and usually causes no harm.
| Worry | What helps |
|---|---|
| Fear of cancer | Understanding your personal risk group and that most people never progress |
| Anxiety before blood tests | Agreeing a clear monitoring plan and knowing whom to contact |
| Family risk | Relatives are not routinely tested, but can mention the family history to their doctor |
| Lifestyle | There are no special diet rules; a healthy weight and regular activity support overall health |
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is MGUS cancer? | No. It is a precursor condition with a small risk of becoming cancer |
| Will it turn into myeloma? | Most people never develop myeloma; the risk is about 1% per year |
| Can MGUS go away? | Usually it persists, though levels may stay stable for decades |
| Do I need treatment? | No, unless the protein is causing organ damage (MGRS or MGCS) |
| Can I do anything to lower the risk? | No proven measures exist, but keeping healthy and attending follow-up is important |
12. Questions to ask your doctor
- What type of MGUS do I have, and what is my risk group?
- How often will I need blood tests, and who will arrange them?
- Do I need a bone marrow test or scans?
- Which symptoms should make me contact you sooner?
- Should I have a bone density scan?
- Could my MGUS be linked to any of my other health problems, such as kidney or nerve problems?
Resources
- Kyle, R.A. et al. (2002) ‘A long-term study of prognosis in monoclonal gammopathy of undetermined significance’, New England Journal of Medicine, 346(8), pp. 564-569.
- Kyle, R.A. et al. (2006) ‘Prevalence of monoclonal gammopathy of undetermined significance’, New England Journal of Medicine, 354(13), pp. 1362-1369.
- Kyle, R.A. et al. (2018) ‘Long-term follow-up of monoclonal gammopathy of undetermined significance’, New England Journal of Medicine, 378(3), pp. 241-249.
- Rajkumar, S.V. et al. (2005) ‘Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance’, Blood, 106(3), pp. 812-817.
- Rajkumar, S.V. et al. (2014) ‘International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma’, The Lancet Oncology, 15(12), pp. e538-e548.
- Landgren, O. et al. (2009) ‘Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study’, Blood, 113(22), pp. 5412-5417.
- Leung, N. et al. (2019) ‘The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group’, Nature Reviews Nephrology, 15(1), pp. 45-59.
- Fermand, J.P. et al. (2018) ‘Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications’, Blood, 132(14), pp. 1478-1485.
- National Cancer Institute (2026) Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.